Viatris (VTRS) said Monday that it filed supplemental new drug applications to Japan's Ministry of Health, Labor and Welfare for approval of Effexor SR Capsules to treat adults with generalized anxiety disorder.
The application follows a phase 3 randomized, double-blind study in Japan which met its primary objective of superiority over a placebo at eight weeks as well as seven secondary efficacy endpoints, the company said.
Effexor is currently approved in Japan to treat major depressive disorder in adults, Viatris said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。